GLAND PHARMA LIMITED

November 24, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Receipt of EIR from USFDA for Company's VSEZ Sterile Oncology Formulations Facility

Ref: Announcement made by the Company dated September 01, 2026

In continuation of our intimation dated September 01, 2026; this is to inform you that following the routine Good Manufacturing Practice (GMP) Inspection at the Company's VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam between August 24, 2026 and September 01, 2026; the Company has received an Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection by classifying the Facility as "No Action Indicated" ("NAI").

Request to take the above information on record.

Yours truly,

For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.11.24 11:56:55 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer